{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:11:21Z","timestamp":1778584281465,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03537-z","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:34:40Z","timestamp":1773743680000},"page":"1855-1868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative"],"prefix":"10.1007","volume":"43","author":[{"given":"Sean","family":"Khozin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Galante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Nussbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mothaffar F.","family":"Rimawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"5","key":"3537_CR1","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.2083","volume":"109","author":"HG Eichler","year":"2021","unstructured":"Eichler HG, Pignatti F, Schwarzer-Daum B, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021;109(5):1212\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3537_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.2474","volume":"111","author":"CA Purpura","year":"2022","unstructured":"Purpura CA, Garry EM, Honig N, Case A, Rassen JA. The role of real-world evidence in FDA-approved new drug and biologics license applications. Clin Pharmacol Ther. 2022;111(1):135\u201344.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"3537_CR3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","volume":"34","author":"L Castelo-Branco","year":"2023","unstructured":"Castelo-Branco L, Pellat A, Martins-Branco D, et al. ESMO guidance for reporting oncology real-world evidence (GROW). Ann Oncol. 2023;34(12):1097\u2013112.","journal-title":"Ann Oncol"},{"key":"3537_CR4","doi-asserted-by":"publisher","first-page":"e5715","DOI":"10.1002\/pds.5715","volume":"33","author":"M Rahman","year":"2024","unstructured":"Rahman M, Dal Pan G, Stein P, et al. When can real-world data generate real-world evidence? Pharmacoepidemiol Drug Saf. 2024;33:e5715.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"3537_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","volume":"22","author":"F Liu","year":"2022","unstructured":"Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022;22(1):287.","journal-title":"BMC Med Res Methodol"},{"key":"3537_CR6","doi-asserted-by":"publisher","first-page":"e2400091","DOI":"10.1200\/CCI.24.00091","volume":"8","author":"BA McKelvey","year":"2024","unstructured":"McKelvey BA, Garrett-Mayer E, Rivera DR, et al. Evaluation of real-world tumor response derived from electronic health record data sources: a feasibility analysis in patients with metastatic non-small cell lung cancer treated with chemotherapy. JCO Clin Cancer Inform. 2024;8:e2400091.","journal-title":"JCO Clin Cancer Inform"},{"key":"3537_CR7","unstructured":"Friends of Cancer Research. RWE Pilot Projects. [online]. https:\/\/friendsofcancerresearch.org\/rwe-pilots\/. Accessed 3 Feb 2026."},{"key":"3537_CR8","unstructured":"Friends of Cancer Research. Establishing a Framework to Evaluate Real-World Endpoints. Published July 10, 2018. Accessed 3 Feb 2026."},{"key":"3537_CR9","doi-asserted-by":"publisher","first-page":"e2200161","DOI":"10.1200\/CCI.22.00161","volume":"7","author":"BA McKelvey","year":"2023","unstructured":"McKelvey BA, Berk A, Chin L, et al. A study design to harmonize patient-reported outcomes across data sets. JCO Clin Cancer Inform. 2023;7:e2200161.","journal-title":"JCO Clin Cancer Inform"},{"key":"3537_CR10","unstructured":"Duke-Margolis Institute for Health Policy. A Roadmap for Developing Study Endpoints in Real-World Settings. Published 28 Aug 2020. Accessed 3 Feb 2026."},{"key":"3537_CR11","unstructured":"Oehrlein EM, Perfetto EM, Schoch S, et al. Patient-Centered Real-World Evidence: Methods Recommendations from an Evidence-Based Consensus Process. Published May 2021. Accessed 3 Feb 2026."},{"issue":"7","key":"3537_CR12","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s12325-025-03201-y","volume":"42","author":"S Khozin","year":"2025","unstructured":"Khozin S, Dreyer NA, Galante D, et al. Real-world evidence acceptability and use in breast cancer treatment decision-making in the united states: call-to-action from a multidisciplinary think tank. Adv Ther. 2025;42(7):2973\u201387.","journal-title":"Adv Ther"},{"issue":"4","key":"3537_CR13","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado A, Guddati AK. Clinical endpoints in oncology\u2014a primer. Am J Cancer Res. 2021;11(4):1121\u201331.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"3537_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.medj.2022.06.007","volume":"3","author":"DV Araujo","year":"2022","unstructured":"Araujo DV, Soler JA, de Coriro Lima VC. Patient-centered trials in oncology: time for a change. Med. 2022;3(7):445\u20139.","journal-title":"Med"},{"issue":"1","key":"3537_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s43441-020-00193-5","volume":"55","author":"RJ LoCasale","year":"2021","unstructured":"LoCasale RJ, Pashos CL, Gutierrez B, et al. Bridging the gap between RCTs and RWE through endpoint selection. Ther Innov Regul Sci. 2021;55(1):90\u20136.","journal-title":"Ther Innov Regul Sci"},{"key":"3537_CR16","doi-asserted-by":"publisher","first-page":"1264861","DOI":"10.3389\/fonc.2023.1264861","volume":"13","author":"PA Kaufman","year":"2023","unstructured":"Kaufman PA, Neuberger E, Schwartz NRM, et al. Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer. Front Oncol. 2023;13:1264861.","journal-title":"Front Oncol"},{"issue":"6","key":"3537_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.eururo.2019.07.048","volume":"76","author":"S Dudani","year":"2019","unstructured":"Dudani S, Graham J, Wells JC, et al. First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the International Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. 2019;76(6):861\u20137.","journal-title":"Eur Urol"},{"issue":"7","key":"3537_CR18","doi-asserted-by":"publisher","first-page":"e000399","DOI":"10.1136\/esmoopen-2018-000399","volume":"3","author":"Y Shinno","year":"2018","unstructured":"Shinno Y, Goto Y, Watanabe S, et al. Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. ESMO Open. 2018;3(7):e000399.","journal-title":"ESMO Open"},{"issue":"5","key":"3537_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/annonc\/mdz060","volume":"30","author":"GM Blumenthal","year":"2019","unstructured":"Blumenthal GM, Gong Y, Kehl K, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019;30(5):830\u20138.","journal-title":"Ann Oncol"},{"key":"3537_CR20","doi-asserted-by":"publisher","first-page":"102264","DOI":"10.1016\/j.ctrv.2021.102264","volume":"100","author":"A Inotai","year":"2021","unstructured":"Inotai A, \u00c1gh T, Maris R, et al. Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. Cancer Treat Rev. 2021;100:102264.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"3537_CR21","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1007\/s11136-020-02604-4","volume":"29","author":"AKM Claessens","year":"2020","unstructured":"Claessens AKM, Ramaekers BLT, Lobbezoo DJA, et al. Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry. Qual Life Res. 2020;29(12):3363\u201374.","journal-title":"Qual Life Res"},{"issue":"13","key":"3537_CR22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/1759-7714.15287","volume":"15","author":"YF Chau","year":"2024","unstructured":"Chau YF, Zhou H, Chen B, et al. Screening for depression and anxiety in lung cancer patients: a real-world study using GAD-7 and HADS. Thorac Cancer. 2024;15(13):1041\u20139.","journal-title":"Thorac Cancer"},{"issue":"1","key":"3537_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s12877-024-05152-5","volume":"24","author":"DN Sanchez","year":"2024","unstructured":"Sanchez DN, Derks MGM, Verstijnen JA, et al. Frequency of use and characterization of frailty assessments in observational studies on older women with breast cancer: a systematic review. BMC Geriatr. 2024;24(1):563.","journal-title":"BMC Geriatr"},{"issue":"8","key":"3537_CR24","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1007\/s11136-023-03390-5","volume":"32","author":"MN Murugappan","year":"2023","unstructured":"Murugappan MN, King-Kallimanis BL, Bhatnagar V, et al. Measuring frailty using patient-reported outcomes (PRO) data: a feasibility study in patients with multiple myeloma. Qual Life Res. 2023;32(8):2281\u201392.","journal-title":"Qual Life Res"},{"key":"3537_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/CCI.20.00125","volume":"5","author":"B Walker","year":"2021","unstructured":"Walker B, Boyd M, Aguilar K, et al. Comparisons of real-world time-to-event end points in oncology research. JCO Clin Cancer Inform. 2021;5:45\u20136.","journal-title":"JCO Clin Cancer Inform"},{"key":"3537_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.6520","author":"C Labaki","year":"2022","unstructured":"Labaki C, Bakouny Z, Sanglier T, et al. Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer A real-world experience. Ann Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.6520.","journal-title":"Ann Oncol"},{"key":"3537_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19135","author":"MS Walker","year":"2020","unstructured":"Walker MS, Herms L, Miller PJE. Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e19135.","journal-title":"J Clin Oncol"},{"key":"3537_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00155","volume":"3","author":"M Stewart","year":"2019","unstructured":"Stewart M, Norden AD, Dreyer N, et al. An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non-small-cell lung cancer. JCO Clin Cancer Inform. 2019;3:1\u201315.","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"3537_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"issue":"1","key":"3537_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1200\/JOP.2010.000076","volume":"7","author":"J Hohneker","year":"2011","unstructured":"Hohneker J, Shah-Mehta S, Brandt PS. Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract. 2011;7(1):65\u20137.","journal-title":"J Oncol Pract"},{"key":"3537_CR31","doi-asserted-by":"publisher","first-page":"e389838","DOI":"10.1200\/EDBK_389838","volume":"43","author":"A Acu\u00f1a-Villaordu\u00f1a","year":"2023","unstructured":"Acu\u00f1a-Villaordu\u00f1a A, Baranda JC, Boehmer J, Fashoyin-Aje L, Gore SD. Equitable access to clinical trials: how do we achieve it? Am Soc Clin Oncol Educ Book. 2023;43:e389838.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"3537_CR32","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","volume":"3","author":"YY Tan","year":"2022","unstructured":"Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43\u2008895 trials and 5\u2008685\u2008738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022;3(10):e674\u201389.","journal-title":"Lancet Healthy Longev"},{"issue":"9","key":"3537_CR33","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/ijc.35053","volume":"155","author":"J Bhimani","year":"2024","unstructured":"Bhimani J, O\u2019Connell K, Persaud S, et al. Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancer. Int J Cancer. 2024;155(9):1577\u201392.","journal-title":"Int J Cancer"},{"issue":"1","key":"3537_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","volume":"10","author":"AM Peterson","year":"2007","unstructured":"Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3\u201312.","journal-title":"Value Health"},{"issue":"1","key":"3537_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/cts.12683","volume":"13","author":"YF Ho","year":"2020","unstructured":"Ho YF, Hu FC, Lee PI. The advantages and challenges of using real-world data for patient care. Clin Transl Sci. 2020;13(1):4\u20137.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"3537_CR36","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","volume":"5","author":"MJ Stirratt","year":"2015","unstructured":"Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5(4):470\u201382.","journal-title":"Transl Behav Med"},{"key":"3537_CR37","unstructured":"Fleege NMG, Bunt S, Mecham B, et al. Disparities in mental health screening for veteran women with a new diagnosis of breast cancer. Presented at: 2024 ASCO Quality Care Symposium; September 30, 2024; Chicago, Illinois."},{"issue":"2","key":"3537_CR38","doi-asserted-by":"publisher","first-page":"pkaf012","DOI":"10.1093\/jncics\/pkaf012","volume":"9","author":"I Arana","year":"2025","unstructured":"Arana I, Liu R, Kushi L, Hahn E, Ragavan M. Screening for comprehensive social needs in patients with cancer: a narrative review. JNCI Cancer Spectr. 2025;9(2):pkaf012.","journal-title":"JNCI Cancer Spectr"},{"issue":"5","key":"3537_CR39","doi-asserted-by":"publisher","first-page":"e70167","DOI":"10.1002\/pon.70167","volume":"34","author":"M Kim","year":"2025","unstructured":"Kim M, Kang KJ, Ryu S. Effects of web-based interventions on anxiety and depression in patients with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Psychooncology. 2025;34(5):e70167.","journal-title":"Psychooncology"},{"key":"3537_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jad.2025.01.152","volume":"376","author":"P Alves","year":"2025","unstructured":"Alves P, Marci CD, Cohen-Stavi CJ, Whelan KM, Boussios C. A machine learning model using clinical notes to estimate PHQ-9 symptom severity scores in depressed patients. J Affect Disord. 2025;376:216\u201324.","journal-title":"J Affect Disord"},{"issue":"2","key":"3537_CR41","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/tbm\/iby123","volume":"9","author":"SL Ehlers","year":"2019","unstructured":"Ehlers SL, Davis K, Bluethmann SM, et al. Screening for psychosocial distress among patients with cancer: implications for clinical practice, healthcare policy, and dissemination to enhance cancer survivorship. Transl Behav Med. 2019;9(2):282\u201391.","journal-title":"Transl Behav Med"},{"issue":"12","key":"3537_CR42","first-page":"5589","volume":"12","author":"HH Tsai","year":"2022","unstructured":"Tsai HH, Yu JC, Hsu HM, et al. The impact of frailty on breast cancer outcomes: evidence from analysis of the Nationwide Inpatient Sample, 2005\u20132018. Am J Cancer Res. 2022;12(12):5589\u201398.","journal-title":"Am J Cancer Res"},{"issue":"26","key":"3537_CR43","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","volume":"41","author":"W Dale","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR, et al. Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol. 2023;41(26):4293\u2013312.","journal-title":"J Clin Oncol"},{"key":"3537_CR44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.12051","author":"JL Shaia","year":"2022","unstructured":"Shaia JL, Liu R, Sun H, et al. Nurse navigator\u2013initiated geriatric assessments in hematology\/oncology clinics. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.12051.","journal-title":"J Clin Oncol"},{"key":"3537_CR45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.12055","author":"A Arora","year":"2022","unstructured":"Arora A, Sun H, Shaia JL, et al. Using G8 and carg toxicity score to predict emergency room (ER) visits, hospitalizations, and mortality in older patients with newly diagnosed cancer. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.12055.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3537_CR46","doi-asserted-by":"publisher","first-page":"e193538","DOI":"10.1001\/jamanetworkopen.2019.3538","volume":"2","author":"EL George","year":"2019","unstructured":"George EL, Arya S. The importance of incorporating frailty screening into surgical clinical workflow. JAMA Netw Open. 2019;2(5):e193538.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"3537_CR47","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/S2666-7568(21)00029-5","volume":"2","author":"JTY Soong","year":"2021","unstructured":"Soong JTY. Frailty measurement in routinely collected data: challenges and benefits. Lancet Healthy Longev. 2021;2(3):e117\u20138.","journal-title":"Lancet Healthy Longev"},{"key":"3537_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12877-015-0078-0","volume":"15","author":"LP Op het Veld","year":"2015","unstructured":"Op het Veld LP, van Rossum E, Kempen GI, de Vet HC, Hajema K, Beurskens AJ. Fried phenotype of frailty: cross-sectional comparison of three frailty stages on various health domains. BMC Geriatr. 2015;15:77.","journal-title":"BMC Geriatr"},{"issue":"22","key":"3537_CR49","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","volume":"291","author":"VH Murthy","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720\u20136.","journal-title":"JAMA"},{"key":"3537_CR50","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s12885-015-1696-9","volume":"15","author":"SL Gomez","year":"2015","unstructured":"Gomez SL, Shariff-Marco S, Von Behren J, et al. Representativeness of breast cancer cases in an integrated health care delivery system. BMC Cancer. 2015;15:688.","journal-title":"BMC Cancer"},{"issue":"3","key":"3537_CR51","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10549-021-06323-3","volume":"189","author":"CH Yan","year":"2021","unstructured":"Yan CH, Coleman C, Nabulsi NA, et al. Associations between frailty and cancer-specific mortality among older women with breast cancer. Breast Cancer Res Treat. 2021;189(3):769\u201379.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3537_CR52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-017-4222-8","volume":"164","author":"JS Mandelblatt","year":"2017","unstructured":"Mandelblatt JS, Cai L, Luta G, et al. Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat. 2017;164(1):107\u201317.","journal-title":"Breast Cancer Res Treat"},{"key":"3537_CR53","doi-asserted-by":"publisher","first-page":"1422475","DOI":"10.3389\/fonc.2024.1422475","volume":"14","author":"A Mehta","year":"2024","unstructured":"Mehta A, Jeon WJ, Nagaraj G. Association of US county-level social vulnerability index with breast, colorectal, and lung cancer screening, incidence, and mortality rates across US counties. Front Oncol. 2024;14:1422475.","journal-title":"Front Oncol"},{"issue":"1","key":"3537_CR54","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41523-023-00595-2","volume":"9","author":"S Puthanmadhom Narayanan","year":"2023","unstructured":"Puthanmadhom Narayanan S, Ren D, Oesterreich S, Lee AV, Rosenzweig MQ, Brufsky AM. Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer. NPJ Breast Cancer. 2023;9(1):90.","journal-title":"NPJ Breast Cancer"},{"issue":"20","key":"3537_CR55","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.3390\/cancers16203442","volume":"16","author":"P Fedele","year":"2024","unstructured":"Fedele P, Landriscina M, Moraca L, et al. Evaluating CDK4\/6 inhibitor therapy in elderly patients with metastatic hormone receptor-positive, HER2-negative breast cancer: a retrospective real-world multicenter study. Cancers (Basel). 2024;16(20):3442.","journal-title":"Cancers (Basel)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03537-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03537-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03537-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:25:08Z","timestamp":1778581508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03537-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3537"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03537-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"17 March 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sean Khozin is co-founder and Principal at Phyusion, LLC, providing advisory services to life sciences companies. Nancy Dreyer has received honoraria for consulting from Pfizer. Raymond Liu has received research funding (to institute) from AstraZeneca, Biotheranostics, Beigene, Exact Sciences, and Genentech. Peter Neumann has received honoraria for consulting from Pfizer. Nathan Nussbaum has equity ownership in Verily Life Sciences. Joyce O\u2019Shaughnessy has received honoraria for consulting and\/or advisory boards from AbbVie Inc., Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Fishawack Health, G1 Therapeutics, Genzyme, GlaxoSmithKline, Genentech, Gilead Sciences, LillyLoxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, and Veru. Mothaffar Rimawi has received honoraria for consulting from Novartis, Pfizer, AstraZeneca, Gilead, Sermonix, Stemline Therapeutics, and Tempus AI. Hope Rugo has received honoraria for consulting and\/or advisory from Napo, Bristol Myers Squibb, Helsinn, and BioNTech; and institutional research support to her former institution, UCSF, from AstraZeneca, Gilead Sciences, Inc., Lilly, Merck & Co., Daiichi Sankyo, Inc., Novartis Pharmaceuticals, Pfizer, F. Hoffman-La Roche\/AG\/Genentech, Stemline Therapeutics, Ambryx. Sara Tolaney has received honoraria for consulting and\/or advisory role from Novartis, Pfizer\/SeaGen, Merck, Eli Lilly, AstraZeneca, Genentech\/Roche, Eisai, Sanofi, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gilead, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Umoja Biopharma, Artios Pharma, Menarini\/Stemline, Aadi Bio, Bayer, Incyte Corp, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Systimmune, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech; research funding (all to institute) from Genentech\/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Gilead, Seattle Genetics, OncoPep, Daiichi Sankyo, Menarini\/Stemline; and travel support from Eli Lilly, Sanofi, Gilead, Jazz, and BioNTech. Adam Brufsky has received honoraria for consulting from AstraZeneca, Novartis, Lilly, Genetech\/Roche, Daiichi Sankyo, Merck, Agendia, Sanofi, Pfizer, Puma, Myriad, Gilead, and Bria Cell; and research support from Agendia and AstraZeneca. Dominic Galante and Marisa Weiss have nothing to disclose. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any new studies with human participants or animals performed by any of the authors. All members of TRIUMPH were fully informed and consented to their thoughts being formulated into a manuscript, invited to contribute as authors on this article, and present as authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}